Literature DB >> 18231910

Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis.

Na-Ri Lee1, Eun-Kee Song, Kyu Yun Jang, Ha Na Choi, Woo Sung Moon, Keunsang Kwon, Ju-Hyung Lee, Chang-Yeol Yim, Jae-Yong Kwak.   

Abstract

Tumor-infiltrating immune cells perform a crucial function in host immune reactions against diffuse large B-cell lymphoma (DLBCL). In this study, we have identified a subset of tumor-infiltrating FOXP3-positive regulatory T cells (Tregs) in the initial DLBCL biopsy specimens, and have evaluated their prognostic significance. Ninety six patients with DLBCL were evaluated retrospectively. The pattern of FOXP3 protein expression was evaluated using standard immunohistochemistry in paraffin-embedded tissue samples. Sixty seven of all 96 specimens were stained with antibodies for CD-10, bcl-6 and MUM1 via tissue microarray (TMA) to classify the cases into a germinal center B-cell like (GCB) group and a non-GCB group. The median overall survival (OS) was 28 months. As compared with the others, the patients with higher percentages of FOXP3-positive Tregs on initial tumor biopsy evidenced a significantly longer OS (p = 0.003). Patients classified into the GCB group evidenced a significantly longer OS as compared with the non-GCB group (p = 0.008). When the prognostic factors were evaluated via a multivariate model, the international prognostic index and the percentage of infiltrating FOXP3-positive Tregs in the initial biopsy were identified as independent predictors of OS. In conclusion, the presence of an increased percentage of FOXP3-positive Tregs in DLBCL is predictive of better prognoses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18231910     DOI: 10.1080/10428190701824536

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  29 in total

Review 1.  Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.

Authors:  M P Bernard; S Bancos; P J Sime; R P Phipps
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

2.  Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma.

Authors:  Matthew J Ahearne; Kaljit Bhuller; Roger Hew; Hazem Ibrahim; Kikkeri Naresh; Simon D Wagner
Journal:  Virchows Arch       Date:  2014-07-11       Impact factor: 4.064

3.  A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix.

Authors:  Walayat Shah; Xiaofei Yan; Li Jing; Yi Zhou; Hongwei Chen; Yili Wang
Journal:  Cell Mol Immunol       Date:  2010-11-22       Impact factor: 11.530

4.  Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified.

Authors:  Shoko Nakayama; Taiji Yokote; Toshikazu Akioka; Nobuya Hiraoka; Uta Nishiwaki; Takuji Miyoshi; Kazuki Iwaki; Ayami Takayama; Yuki Masuda; Jun Hatooka; Mayumi Fujimoto; Yasuichiro Nishimura; Motomu Tsuji
Journal:  Blood Adv       Date:  2017-03-06

Review 5.  T regulatory cells in B-cell malignancy - tumour support or kiss of death?

Authors:  Camilla A Lindqvist; Angelica S I Loskog
Journal:  Immunology       Date:  2012-04       Impact factor: 7.397

6.  Exclusion of cytoplasmic fragments in flow cytometric analysis of lymph node samples from dogs with lymphoma using membrane-permeable violet laser-excitable DNA-binding fluorescent dye (DyeCycle Violet).

Authors:  Daisuke Ito; Timothy D O'Brien; Jaime F Modiano
Journal:  Vet Clin Pathol       Date:  2010-09-21       Impact factor: 1.180

Review 7.  Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.

Authors:  Ruifang Sun; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2016-08-01       Impact factor: 7.842

8.  Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions.

Authors:  Claire Germain; Thierry Guillaudeux; Elisabeth D Galsgaard; Catherine Hervouet; Nedra Tekaya; Anne-Sophie Gallouet; Julien Fassy; Franck Bihl; Gwenola Poupon; Anne Lazzari; Pieter Spee; Fabienne Anjuère; Céline Pangault; Karin Tarte; Patrick Tas; Luc Xerri; Veronique M Braud
Journal:  Oncoimmunology       Date:  2015-04-08       Impact factor: 8.110

9.  Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.

Authors:  Roch Houot; Matthew J Goldstein; Holbrook E Kohrt; June H Myklebust; Ash A Alizadeh; Jack T Lin; Jonathan M Irish; James A Torchia; Arne Kolstad; Lieping Chen; Ronald Levy
Journal:  Blood       Date:  2009-07-29       Impact factor: 22.113

10.  Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways.

Authors:  Yi-Lan Zhang; Jiang Li; Hao-Yuan Mo; Fang Qiu; Li-Min Zheng; Chao-Nan Qian; Yi-Xin Zeng
Journal:  Mol Cancer       Date:  2010-01-10       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.